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Genetic instability of the mitochondrial genome
(mtDNA) plays an important role in human aging
and disease. Thus far, it has proven difficult to
develop successful treatment strategies for diseases
that are caused bymtDNA instability. To address this
issue, we developed a model of mtDNA disease in
the nematode C. elegans, an animal model that can
rapidly be screened for genes and biological path-
ways that reduce mitochondrial pathology. These
worms recapitulate all the major hallmarks of mtDNA
disease in humans, including increased mtDNA
instability, loss of respiration, reduced neuromus-
cular function, and a shortened lifespan. We found
that these phenotypes could be rescued by inter-
vening in numerous biological pathways, including
IGF-1/insulin signaling, mitophagy, and the mito-
chondrial unfolded protein response, suggesting
that it may be possible to ameliorate mtDNA disease
through multiple molecular mechanisms.INTRODUCTION
Energy animates life. Whether it’s protein synthesis, autophagy,
or signal transduction, almost every biological process is driven
by the consumption of energy. Most of this energy is generated
by mitochondria, small tubular organelles that are frequently
called the powerhouses of our cells. To optimize energy produc-
tion, mitochondria carry their own genome called ‘‘mtDNA,’’ a
small, circular molecule that encodes numerous protein prod-
ucts that are essential to ATP synthesis (Anderson et al., 1981).
As a result, loss or mutation of mtDNA invariably affects energy
production, which is particularly harmful to cells with high energy
demands such as neurons and muscle fibers (Wallace, 2005).
Most diseases caused by mtDNA instability are therefore char-
acterized by some form of neuromuscular dysfunction. For
example, point mutations, deletions, or overt loss of mtDNA
molecules can result in premature deafness, myopathy, or se-
vere encephalomyopathy in children (Saneto and Sedensky,This is an open access article under the CC BY-N2013) and contributes to neurodegeneration (Kraytsberg et al.,
2006) and muscle wasting (Wanagat et al., 2001) in aging adults.
In most cases, mtDNA instability arises spontaneously, although
it also can be caused by mutations in DNA polymerase g, the
enzyme that replicates the mitochondrial genome. Thus, the
impact of mtDNA instability on human aging and disease is
well documented. To this day though, no child has ever been
cured of an mtDNA disease, nor does a treatment exist for the
mtDNA component of age-related diseases. Although it is now
possible to manage the symptoms of a number of pediatric
mtDNA diseases, two bottlenecks have traditionally kept the sci-
entific community from developing a more robust treatment
strategy: a shortage of animal models and a lack of promising
molecules to target. Here, we address these issues by establish-
ing a model of mtDNA disease in worms that can give rise to
countless additional models with the proper breeding scheme.
Moreover, because worms can be easily manipulated by genetic
and pharmaceutical means, we were able to use RNAi, drugs,
and genetic mutants to identify multiple cellular pathways that
can ameliorate the pathological consequences of mtDNA insta-
bility on organismal health, thus providing potential targets for
therapeutic intervention. Together, these results suggest that
multiple pathways may have evolved to prevent mtDNA disease,
underlining the central role that energy plays in cellular life.
RESULTS
A Model of mtDNA Disease in C. elegans
To successfully design a therapeutic strategy for mtDNA dis-
ease, it will be essential to identify cellular mechanisms that
can either increase or decrease the pathology that is caused
by mtDNA instability. These experiments will reveal promising
targets that can be exploited for therapeutic intervention, and
may provide valuable insight into the basic biology that underlies
mitochondrial function. Identifying these mechanisms requires a
flexible animal model that is well suited for ‘‘discovery experi-
ments.’’ The most promising model available today is the mito-
chondrial mutator mouse (Kujoth et al., 2005; Trifunovic et al.,
2004). This mousemodel carries an error-prone copy of DNA po-
lymerase g (PolgAD257A), the enzyme that replicates the mito-
chondrial genome. Because of error-prone DNA replication,
the PolgAD257 mice exhibit a >100-fold increase in mtDNACell Reports 22, 3115–3125, March 20, 2018 3115
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Figure 1. Characterization of the polg-1(srh1) Worms
(A) The exonuclease (green) domain of DNA polymerase g contains three highly conserved regions (red) that control the fidelity of DNA synthesis, including an
aspartic acid in exonuclease domain II that is essential for the proofreading activity of polymerase g across the tree of life. We used CRISPR/Cas9 technology to
mutate this residue to alanine in the error-prone allele polg-1(srh1).
(B) The mtDNA mutation frequency of the polg-1(srh1) worms is >70-fold higher compared to WT worms.
(C) The mutation spectrum of WT and polg-1(srh1) depicted as peaks above and below the WT nucleotide according to standard electrophoretogram color
coding (red, T; blue, C; black, G; green, A). The percentage of each type of mutation is listed by the peaks.
(D) The mtDNA copy number is reduced by 56% in the polg-1(srh1) worms.
(E) The basal respiration of polg-1(srh1) worms worsens with age compared to WT worms.
(F) The mitochondria of polg-1(srh1) worms display reduced reserve capacity upon FCCP treatment at 5 days of age.
(G and H) Confocal images of day 10 polg-1(srh1) and WT worms (G) do not reveal a significant difference in oxidation stress (H).
(legend continued on next page)
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mutations, which results in extensive mtDNA disease (Kujoth
et al., 2005; Trifunovic et al., 2004; Vermulst et al., 2007, 2008).
However, logistical considerations prohibit these mice from be-
ing screened en masse to identify genes or molecular pathways
that modulate their pathology. Therefore, we recreated the
PolgAD257A mutation in C. elegans, a genetically tractable model
organism that is amenable to high-throughput screens. Using
CRISPR/Cas9 technology, we directly edited the polg-1 gene
(theC. elegans homolog of PolgA) and introduced the analogous
D207A mutation (polg-1(srh1)) (Figure 1A). Similar to the mutator
mice, we found that the polg-1(srh1) worms display a large
increase in mtDNA mutations (Vermulst et al., 2007, 2008) (Fig-
ure 1B), which was primarily driven by C:G > T:A transitions (Fig-
ure 1C). These transitions were not equally distributed over the
TaqI restriction site, despite the fact that it is a palindrome, sug-
gesting that polg-1-mediated mutagenesis has a substantial
strand bias (Figure 1C). Moreover, homozygous carriers of the
polg-1(srh1) allele displayed a 50% loss in mtDNA copy num-
ber (Figure 1D), mirroring the mtDNA depletion of homozygous
mutator mice. Thus, even though mtDNA is replicated differently
in worms compared to mice (Lewis et al., 2015), the polg-1(srh1)
worms closely mimic the genetic instability of the mutator mice
and display an increased rate of mtDNA mutation and depletion,
two forms of mtDNA instability that cause mtDNA disease in hu-
mans (Copeland, 2008; El-Hattab and Scaglia, 2013).
Mutator Worms Replicate Major Hallmarks of mtDNA
Disease in Humans
In human patients, mtDNA instability invariably results in mito-
chondrial dysfunction. To determine whether the mutator worms
display mitochondrial dysfunction as well, we analyzed intact
worms by respirometry. We found that at day 1 of adulthood,
the mutator worms respire at the same rate as wild-type (WT)
worms; however, at 11 days of age, they display a 50%
decrease in oxygen consumption (Figure 1E), indicating that
they suffer from a progressive decline in mitochondrial function.
Closer examination showed that this decline starts at 5 days of
age, when basal respiration is optimal, but the reserve capacity
of mitochondria has been reduced to 50% of WT levels (Figures
1F, S1A, and S1B). However, similar to the mutator mice,
reduced respiration did not result in overt production of reactive
oxidative species (Figures 1G, 1H, and S1C–S1F) (Kujoth et al.,
2005; Trifunovic et al., 2005). The most prevalent symptom of
inherited, as well as age-related mtDNA disease is neuromus-
cular dysfunction (Wallace, 2010). To determine whether the
polg-1(srh1) worms display neuromuscular dysfunction as well,
we tested their locomotion toward a chemo-attractant. This
assay tests the ability of the worms to sense the chemo-attrac-
tant (Wes and Bargmann, 2001) (neuronal function), as well as
their ability to crawl toward it (muscle function) (Kashyap et al.,(I–K) Neuromuscular function assessed by chemotaxis (I), thrashing (J), and a
compared to WT animals.
(L) The polg-1(srh1) worms have a median lifespan of 13 days compared to 16 d
Data for WT and polg-1(srh1) worms are in blue and pink, respectively (in B, D–F
Bar graphs represent the mean ± SEM of at least three biological replicates, an
Unpaired t tests were performed to determine significance (*p < 0.05, **p < 0.01
Also see Figure S1 and Movies S1 and S2.2012). At day 1 of adulthood, the polg-1(srh1) worms were able
to reach the chemo-attractant with the same efficiency as WT
worms; however, as the polg-1(srh1) worms grew older, they
became increasingly incapable of accomplishing this task (Fig-
ure 1I). On average, this phenotype emerged at 5 days of adult-
hood, coinciding with the onset of mitochondrial dysfunction,
and worsened as the worms grew older (Figure 1I). To better un-
derstand the physiological underpinnings of this neuromuscular
dysfunction, we used a ‘‘gentle touch’’ and ‘‘thrashing’’ assay.
The gentle touch assay documents the ability of worms to detect
a gentle tap on their head and their tail, which primarily tests the
function of highly specialized mechanosensory neurons (Hobert
et al., 1999). This assay revealed that the mutator worms are
increasingly unresponsive to gentle touches, which became
significantly different from WT worms at day 7 of adulthood
and lasted until measurements concluded at day 10 (Figure 1J).
The thrashing assay documents the number of times worms
bend their bodies over in rapid succession in liquid media (Ban-
sal et al., 2015; Han and Beckerle, 2009). Similar to the gentle
touch assay, we found that the polg-1(srh1) worms display
an age-related decrease in thrashing (Figure 1K; Movies S1
and S2). However, in contrast to the gentle touch assay, this
phenotype was more severe and emerged concurrently with
the chemotaxis defect at day 5 of adulthood. This observation
suggests that the dysfunction of the polg-1(srh1) worms high-
lighted by the chemotaxis assay is most likely due to an inability
to move, and not an inability to sense the chemoattractant.
Further experimentation will be required to determine whether
their inability to move is caused by dysfunction of the muscle
cells themselves, or the motor neurons that innervate them.
The neuromuscular dysfunction associated with mtDNA disease
in humans is typically incompatible with normal lifespan (Wal-
lace, 2005, 2010). To determine whether the polg-1(srh1) worms
display a shortened lifespan aswell, we compared the lifespan of
WTworms to polg-1(srh1)worms and found that the polg-1(srh1)
worms are indeed shorter lived than WT animals (Figure 1l),
further confirming the extent of their disease, and their similarity
to the short lived mutator mice (Trifunovic et al., 2004). Taken
together, these experiments indicate that the polg-1(srh1)
worms recapitulate several hallmarks of mtDNA disease in hu-
mans including increased mtDNA instability, loss of mitochon-
drial respiration, extensive neuromuscular dysfunction, and a
shortened lifespan.
Mutation Load and Tissue Dysfunction of polg-1(srh1)
Worms Worsen over Generations
The number of mutated mtDNA molecules that are transmitted
frommother to child controls the severity and the type of pathol-
ogy that emerges in children (Wallace, 2010). The higher this
number is, the more complex the disease tends to be; however,gentle touch assay (K) reveals increased dysfunction in polg-1(srh1) worms
ays for WT worms (log-rank test p < 0.01).
, and H–L).
d the lifespan assay was performed using at least 100 worms per genotype.
; ns, no significant difference).
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Figure 2. The Phenotype of the polg-1(srh1)
Worms Worsens from Generation to
Generation
(A) The outer circle represents the worm mito-
chondrial genome highlighting the protein-coding
genes (green), rDNA (blue), AT-rich region (yellow),
and all the mutations (red) that arose over 35
generations of maintaining the polg-1(srh1) muta-
tor allele. The inner circle represents the regions
that were sequenced (blue).
(B) mtDNA mutations were tracked over 35 gen-
erations in WT and polg-1(srh1) worms. At gener-
ations 5, 15, 25, and 35, 11 kb of mtDNA of 3
progenies of a single WT and polg-1(srh1)
worm were sequenced. The mutations depicted
here were present in all 3 progenies, indicating that
they were successfully transmitted through the
germline. Three mutations, here denoted in purple,
brown, and orange polg-1(srh1) were present
across multiple generations and showed sub-
stantial genetic drift. No newmutations arose in the
WT strain.
(C–E) Neuromuscular dysfunction was assessed
by chemotaxis (C), thrashing (D), and gentle
touch (E) revealed progressive dysfunction with
increasing generation in the polg-1(srh1) worms.
(F) Representative electrophoretograms tracking
the T2085 deletion that results in an early stop
codon in the ND1 gene in both the parent with
polg-1(srh1) allele and its resultant progeny where
the mutator allele has been mated out. Three in-
dividuals without the polg-1(srh1) allele in the F1
generation, 10 individuals in the F2 generations,
and 21 individuals in the F3 generation were iso-
lated and tested for the transmission of T2085
heteroplasmy in a background WT for polg-1.
Bar graphs represent the mean ± SEM of at least
three biological replicates. Unpaired t tests were
performed to determine significance (*p < 0.05,
**p < 0.01; ns, no significant difference).
Also see Figure S2.it has proven difficult to study germline transmission of mtDNA
mutations in detail, because it is not possible to transform the
mitochondrial genome at will. As a result, researchers are forced
to rely on natural mtDNA variants to decipher the parameters that
regulate mutation inheritance. We reasoned that the increased
mutation rate of the polg-1(srh1) allele could greatly accelerate
the process of isolating organisms with specific mtDNA muta-3118 Cell Reports 22, 3115–3125, March 20, 2018tions of interest, so that novel models of
inherited mtDNA mutations can rapidly
be generated. To test this hypothesis,
we tracked the offspring of individual WT
and polg-1(srh1) worms over 35 genera-
tions and sequenced the mtDNA of 3
siblings at generations 5, 15, 25, and 35.
Over these generations, the mutator
worms accrued an increasing number of
detectable heteroplasmic mutations (Fig-
ures 2A, 2B, and S2), while the mtDNA of
the WT worms remained pristine. Consis-tent with the idea that thesemutations contribute to the dysfunc-
tion of the polg-1(srh1)worms, we found that the performance of
the polg-1(srh1) worms in the chemotaxis (Figure 2C), gentle
touch (Figure 2D) and thrashing (Figure 2E) assay decreased
with increasing generation number. To prevent these genera-
tional effects from confounding our results, all studies were per-
formed on generation-matched worms (generations 27–33).
Figure 3. An RNAi Screen IdentifiedMultiple
Genes That Control mtDNA Disease in the
polg-1(srh1) Worms
(A and B) 20–35 WT (A) and polg-1(srh1) (B) worms
were aged for 5 days and spotted inside the red
circle. A chemo-attractant was spotted 5 cm away
from the worms (green circle), and the worms were
allowed to crawl toward the chemo-attractant for
1 hr. Over this time span, most WT worms reached
the chemo-attractant, while the polg-1(srh1)
worms performed significantly worse.
(C) Twenty 5-day-old polg-1(srh1) adults on RNAi
against age-1 perform similar to WT worms.
(D) A list of genes that rescued the polg-1(srh1)
neuromuscular defect by >30% when suppressed
by RNAi.
See also Figure S3 and Table S1.However, in some cases, the rationale of our experiments
required a change in generation number. If so, this change has
been clearly denoted. We further found that these germline
mutations both increased and decreased over successive
generations, indicating substantial genetic drift. To formally
demonstrate that these mutations can be isolated to study their
inheritance, we decided to remove the error-prone polg-1(srh)
allele from the nuclear genome. We reasoned that this strategy
would prevent additional mutations from accumulating in the
mitochondrial genome, and allow desirable mtDNA mutations
to be fixed in a WT nuclear background. To this end we crossed
the mutagenic polg-1(srh) allele out of a worm that carried a sin-
gle base-pair deletion in the ND1 gene (Figures 2A, 2B, and S2E).
After the removal of the polg-1(srh) allele, we selectively picked
individual progeny from parents with 70% heteroplasmy over
several generations (Figure 2F), and were able to successfully
retain this mtDNA mutation. Interestingly, we found that, three
generations after breeding out the mutator allele, 33% of the
worms laid inviable embryos, 33% of the worms laid progeny
that became larval phase 2 dauers, and 33% of the worms laid
normal embryos that developed fully. This experiment demon-Cell Restrates that it is possible to exploit the
polg-1(srh) worms to generate novel ani-
mal models that display gross phenotypic
abnormalities, and carry highly desirable
mtDNA mutations in their germline, which




The chemotaxis assay described above is
highly quantitative and reproducible, and
tests the most important clinical aspects
of mtDNA disease. Therefore, we used
this assay as a screening tool to identify
genes that can ameliorate the pathology
associatedwithmtDNAdisease (Figure 3).
To this end, we performed a candidate
RNAi screen using >130 RNAi constructsthat control either C. elegans lifespan, overall health, or various
aspects of mitochondrial function, parameters that are likely to
intersect with mtDNA disease. We considered a gene a positive
hit if RNAi against that gene improved the performance of the
mutator worms by >30%. This cutoff is based on the obser-
vation that the inherent variation between randomly selected
polg-1(srh1) worms rarely exceeded this threshold (0 out of 10
trials), indicating a <10% chance of discovering a false positive
(Figure S3A). Second, RNAi against age-1, which we found to
be a potent modulator of mtDNA disease (35% on average) (Fig-
ures 3A–3C), improved the performance of the mutator worms
by >30% in 6 out of 9 trials (Figure S3B), indicating a > 60%
chance of detecting a gene that increases the performance of
the polg-1(srh1)worms by 35%ormore. Excitingly, RNAi against
numerous genes decreased the pathology associated with
mtDNA disease in worms. For example, manipulation of the
insulin growth factor (IGF)-1/insulin signaling (IIS) pathway,
mitophagy, autophagy, apoptosis, and the mitochondrial
unfolded protein response (UPRmt) all ameliorated the neuro-
muscular defect of the polg-1(srh1) worms (Figure 3D). Interest-
ingly, reduced autophagy was previously shown to ameliorateports 22, 3115–3125, March 20, 2018 3119
mitochondrial dysfunction in a model of mitochondrial disease
that is caused by a nuclear mutation (Peng et al., 2015), while
suppression of apoptosis activates the highly beneficial stress
response in worms (Judy et al., 2013). Similarly, mitophagy
and UPRmt are implicated in various diseases that contain a
mitochondrial component (Haynes et al., 2013; Youle andNaren-
dra, 2011). We frequently found that RNAi against multiple com-
ponents of the same pathway rescued the mutator worms,
strongly implicating that pathway in the progression of mtDNA
disease (Figure 3D). Furthermore, we found that pathways that
do not impact mitochondrial biology (such as the unfolded pro-
tein response of the ER) did not alter the performance of the mu-
tator worms (Table S1). To validate the results of our screen and
investigate themolecular mechanisms that underlie our observa-
tions, we picked three pathways that emerged from our screen
and used drugs and genetic mutations to knockout or activate
the molecular pathways they control.
The IGF-1/Insulin signaling pathway emerged as the strongest
modulator of mtDNA disease, as RNAi against age-1, par-5, and
akt-1 all rescued themobility defect of the polg-1(srh1)worms. In
contrast, RNAi against daf-18, which directly opposes AGE-1
(Murphy and Hu, 2013), exacerbated the phenotype of the
polg-1(srh1) worms (Table S1). At a mechanistic level, age-1,
par-5, and akt-1 share a common goal as well: they all increase
the phosphorylation of the transcription factor DAF-16, trapping
it in the cytoplasm and suppressing its activity (Murphy and Hu,
2013). RNAi against age-1, par-5, and akt-1 releases this sup-
pression and allows DAF-16 to translocate to the nucleus where
it initiates a transcriptional program that promotes organismal
health (Kenyon, 2010). Consistent with this idea, we found that
RNAi against daf-16 greatly exacerbated the neuromuscular
defect of the polg-1(srh1)worms (Table S1). To verify our findings
further, we introduced a hypomorph of the IGF-1/insulin receptor
(daf-2(e1370)) into the polg-1(srh1) worms. This allele displays
reduced IIS activity (Kenyon et al., 1993) and consistent with
our RNAi results, we found that it rescued the neuromuscular
defect of the mutator worms (Figure 4A). Conversely, a partial
deletion of daf-16 (daf-16(mu86)) exacerbated their phenotype
(Figure 4B). Thus, these genetic mutations recapitulated
the results of our RNAi screen. We further found that the
daf-2(e1370) allele also improved the basal respiration rate of
the mutator worms (Figure 4C), indicating that reduced IIS activ-
ity improves the mobility of the worms by correcting their under-
lying mitochondrial dysfunction. Interestingly, the daf-2(e1370)
allele also improved mtDNA copy number in the mutator worms
(Figure 4D), suggesting that it can partially rescue the etiology of
the disease itself, although the mutation rate of the polg-1(srh1)
worms was unaffected (Figure 4E).
Our screen further indicated that knockdown of dct-1 and
pdr-1 could rescue the mobility defect of the mutator worms.
Because these genes play a pivotal role in mitophagy (Palikaras
et al., 2015), these results suggest that reduced mitophagy may
be beneficial for the polg-1(srh1)worms. To verify these observa-
tions with a genetic mutant, we introduced the pdr-1(gk448)
allele into the mutator worms. Pdr-1 encodes the C. elegans ho-
molog of the parkin ubiquitin ligase PARK2, and the pdr-1(gk448)
allele carries a partial deletion that greatly reduces mitophagy in
worms (Springer et al., 2005). Consistent with our RNAi screen,3120 Cell Reports 22, 3115–3125, March 20, 2018we found that the pdr-1(gk448) allele rescued the neuromuscular
defect of the polg-1(srh1) worms (Figure 4F). Conversely, expo-
sure of the mutator worms to urolithin A, a drug that induces mi-
tophagy (Ryu et al., 2016), worsened their phenotype (Figure 4G).
Finally, we found that the pdr-1(gk448) allele rescued the basal
respiration rate of the mutator worms (Figure 4H), similar to the
daf-2(e1370) allele. In contrast to the daf-2(e1370) allele though,
we found that the pdr-1(gk448) allele did not alter mtDNA copy
number (Figure 4I) and paradoxically increased the mitochon-
drial mutation frequency by 5.5-fold (Figure 4J).
Finally, our screen indicated that RNAi against the mitochon-
drial protease spg-7 and several components of the electron
transport chain (atp-3, nuo-2, D2030.4, and T02H6.11) rescued
the neuromuscular defect of the mutator worms. Knockdown
of spg-7 or certain components of the electron transport chain
are known to induce the unfolded protein response in mitochon-
dria (Jovaisaite et al., 2014), indicating a possible involvement of
this adaptive stress response in the rescue mechanism. Indeed,
suppression of UPRmt by RNAi against haf-1, atfs-1, and ubl-5,
exacerbated the phenotype of the mutator worms (Table S1).
To further verify the protective role of UPRmt in mtDNA disease
progression, we introduced the deletion allele atfs-1(tm4919)
(Pellegrino and Haynes, 2015) into the polg-1(srh1) background.
Atfs-1 encodes a transcription factor required for UPRmt activa-
tion. Interestingly, we found that homozygous carriers of the
atfs-1(tm4919) allele rendered heterozygous polg-1(srh1)worms
infertile, indicating that loss of UPRmt greatly exacerbates the
phenotype of the polg-1(srh1) worms. Accordingly, we were
unable to generate homozygous polg-1(srh1); atfs-1(tm4919)
worms for experiments. To answer the question of whether acti-
vation of this adaptive response is able to rescue mtDNA dis-
ease, we used a constitutively active atfs-1 allele (atfs-1(et15))
and found that it indeed partially rescued the neuromuscular
defect of the mutator worms (Figure 4K). In addition, this allele
rescued the decreased reserve capacity of mitochondria (Fig-
ure 4L) and slightly increased mtDNA copy number (Figure 4M),
although it did not alter the mtDNA mutation frequency
(Figure 4N).
DISCUSSION
MtDNA instability is associated with a remarkable number of
human diseases. Although it is now possible to manage, and
even improve some of the symptoms of mtDNA disease, there
is currently no cure for either inherited mtDNA diseases or
the mtDNA component of age-related diseases. To address
this problem, we generated a model of mtDNA disease in
C. elegans,which displays two forms of mtDNA instability known
to cause mtDNA disease in humans: mtDNA depletion and
mtDNA mutation. Both of these phenotypes are driven by a
mutant DNA polymerase g, which is a major source of mtDNA
instability in patients as well. As a result, the polg-1(srh1) worms
do notmodel any specificmtDNA disease, but serve as a general
model of mtDNA disease caused by mtDNA instability. The
polg-1(srh1) worms are especially useful because they can
rapidly be screened for large numbers of genes, drugs, and small
molecules that modulate mtDNA disease, which allows them to
serve as a motor for discovery. Moreover, any findings can
Figure 4. Verification of the RNAi Screen with Genetic Mutants and Small Molecules
(A) The daf-2(e1370) allele rescues the neuromuscular defect of 5-day-old polg-1(srh1) worms.
(B) The daf-16(mu86) allele worsens the neuromuscular defect of 5-day-old polg-1(srh1)worms. This set of experiments was performed at generation 7 instead of
generation 30, when the phenotype of themutator worms is not significantly different from theWTworms until 7 days of age. Accordingly, the detrimental effect of
the daf-16(mu86) allele is better illustrated.
(C) The daf-2(e1370) allele rescues the basal respiration rate of 10-day-old polg-1(srh1) worms.
(D and E) The daf-2(e1370) allele (D) increases mtDNA copy number by 118%, but (E) has no effect on the mutation frequency of polg-1(srh1) worms.
(F) The pdr-1(gk448) allele rescues the chemotaxis defect of 5-day-old polg-1(srh1) worms.
(G) Induction of mitopagy with 50 mM urolithin A (UA) worsens the chemotaxis phenotype of the 5-day-old polg-1(srh1) worms.
(H) The pdr-1(gk448) allele rescues the basal respiration rate of 10-day-old polg-1(srh1) worms.
(I and J) The pdr-1(gk448) allele (I) increases mtDNA copy number by 25% and (J) results in a 5.5-fold increase in the mutation frequency of polg-1(srh1) worms.
(K and L) The atfs-1(et15) allele (K) rescues the chemotaxis defect of 5-day-old polg-1(srh1) worms and (L) the reserve capacity of 5-day-old polg-1(srh1) worms.
(M and N) The atfs-1(et15) allele (M) increases mtDNA copy number by 63%, but (N) has no effect on the mutation frequency of polg-1(srh1) worms.
Bar graphs represent the mean ± SEM of at least three biological replicates. Unpaired t tests were performed to determine significance (*p < 0.05, **p < 0.01; ns,
no significant difference).
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immediately be tested in the mitochondrial mutator mice to
determine whether they are translatable to mammalian biology.
Another useful feature of the mutator worms is that they rapidly
accumulate mtDNA mutations in their germline, which allows
for countless additional models of mtDNA disease to be gener-
ated. For example, after crossing the error-prone polg-1(srh1)
allele out of the nuclear genome to prevent further mutation
accumulation, worms with desirable germline mutations could
be used to determine which parameters control the inheritance
of mutated molecules. A similar approach was recently pro-
posed for the mitochondrial mutator mice (Kauppila et al.,
2016). Because mitochondrial research is greatly handicapped
by a lack of inheritedmutant mtDNAmodels, thesewormswould
complement the mtDNA models that can be generated by re-
striction site targeting (Xu et al., 2008) to fill an important void
in the research community.
A second problem that prevents the research community from
developing a treatment for mtDNA disease is the lack of prom-
ising molecules to target. Here, we used the polg-1(srh1) worms
to show that numerous molecular pathways control the severity
of mtDNA disease. The most promising candidate we have iden-
tified thus far is the IGF-1/insulin signaling pathway. It has long
been known that reduced IGF-1/insulin signaling has beneficial
effects on the overall health of organisms (Kenyon, 2010); how-
ever, our results now suggest that for a discrete set of diseases,
reduced IIS activity may also have a direct therapeutic applica-
tion. Since reduced IIS activity increased mtDNA copy number,
this approach may be especially useful for diseases caused by
mtDNA depletion. Second, it is well known that reduced IGF-1
signaling is particularly beneficial to aging organisms (Kenyon,
2010). Since mtDNA mutations and mitochondrial dysfunction
are associated with aging, these findings also provide insight
into the molecular mechanisms by which reduced IGF-1
signaling prevents age-related dysfunction. We further found
that reduced mitophagy could rescue the polg-1(srh1) worms
from mtDNA disease, while increased mitophagy exacerbated
their phenotype. This counter-intuitive observation suggests
that while increased mitophagy is beneficial under normal cir-
cumstances, it can result in an adverse outcome in the context
of disease. One potential explanation for this paradox could be
that in the mutator worms recycled mitochondria are replaced
with equally dysfunctional organelles, leading to futile cycles of
mitophagy and mitochondrial biogenesis that results in further
energy depletion. Interestingly, loss of PARK2 has both benefi-
cial (reduced splenomegaly) and detrimental (substantia nigra)
effects on the mutator mice (Pickrell and Youle, 2015), suggest-
ing that the effect of reduced mitophagy on mammalian biology
is highly cell-type and tissue specific. Another surprising obser-
vation was that reduced mitophagy increased the mutation
burden of the mutator worms. These results suggest that mi-
tophagy can potentially cull mutated mtDNA molecules from
cells, which is consistent with the idea that mitophagy recycles
dysfunctional organelles. Surprisingly though, knocking out
PARK2 in the mitochondrial mutator mice did not seem to result
in an increased mutation frequency. The reason for this discrep-
ancy is currently unclear; however, an important difference be-
tween these organisms is that the mutator mice carry 10-fold
more mutations than the mutator worms, which may limit the3122 Cell Reports 22, 3115–3125, March 20, 2018ability of mitophagy to significantly impact the mutation burden.
Finally, we found that activation of UPRmt could rescue the
neuromuscular defect of the polg-1(srh1) worms. Interestingly,
it was previously shown that a reduction in mtDNA copy number
causes an imbalance in the number of proteins derived from the
nuclear and mitochondrial genome. This imbalance causes pro-
teotoxic stress inside mitochondria by preventing proteins from
finding their natural binding partner, and UPRmt ameliorates
this stress. Since the polg-1(srh1) worms suffer from mtDNA
depletion, we hypothesize that a reduction in proteotoxic stress
partially underlies the improved performance of the polg-1(srh1);
atfs-1(et15) worms.
Taken together, these observations demonstrate that the polg-
1(srh1)worms are a useful model to identifymodulators ofmtDNA
disease.We further note that all of themodifiers we analyzed here
seem to ameliorate mtDNA disease by improving mitochondrial
function, suggesting that theycouldbebeneficial for abroad range
of mtDNA diseases. Moreover, since the genetic instability of the
mutator worms is substantial, thesemodifiers are likely to be fairly
powerful. It is further interesting to note that despite the fact that
few targets are available today, a substantial number of genes
can modulate the pathological consequences of mtDNA insta-
bility, suggesting that numerous targets may exist for therapeutic
treatment ofmtDNAdisease. One potential conclusion from these
observations is that precisely because energy is required for every
biological process in our cells, multiple pathways may have
evolved to manage or prevent mtDNA disease. Using the polg-
1(srh1) worms, the mutator mice, and numerous other models
that arestill on the horizon, it nowfinallymaybepossible to identify
these pathways in a reasonable period of time, which holds enor-
mous promise for our ability to understand the molecular basis of
mtDNA disease and to develop comprehensive treatment plans
for patients.EXPERIMENTAL PROCEDURES
Strains and Growth Conditions
The polg-1(srh1) worms were created using CRISPR/Cas9 technology in
accordance with published protocols (Waaijers et al., 2013) and using the
guide RNA sequence UGAUCGAGCCAGAUGUCGGG and the donor DNA
sequence atcggagagattggaatggaaaaagtgattattggacataatgttggatttgCccgGg
ccCgTtgCcgTgaggcttatcaatcgataaatgggtcaaagattcgatttatggatacaatgtct.
Capitalized bases differ from the WT polg-1 sequence. These changes were
required for changing the aspartic acid at residue 207 to alanine, as well as
inhibiting CRISPR/Cas9 cleavage after integration of the donor DNA. Addi-
tionally, these changes introduced a SmaI restriction site for genotyping
purposes. Like in many other models of mitochondrial dysfunction, we
found that the polg-1(srh1) worms displayed pronounced fertility problems
when in a homozygous state. Therefore, we maintained the polg-1(srh1)
allele as heterozygote animals with the balancer chromosome mnC1 that
carries a pharyngeal fluorescent GFP reporter (CGC strain MT20110). Only
the non-fluorescent homozygous worms were used for experiments. The
daf-2(e1370), daf-16(mu86), pdr-1(gk448), and atfs-1(tm4919) alleles were
obtained from CGC, which is funded by NIH Office of Research Infrastructure
Programs (P40 OD010440). The atfs-1(et15) strain was created by Dr. Marc
Pilon (University of Gothenburg, Sweden) and was obtained from Dr. Cole
Haynes. All strains were backcrossed into the laboratory N2 WT strain at
least four times before comparative experiments were carried out. Strains
were maintained without starvation at 20C for at least two generations prior
to experimental use. The L4 stage of worms was counted as day 0 of adult-
hood for all experiments.
mtDNA Copy Number
mtDNA copy number was determined by qPCR using at least three repli-
cates per genotype by adapting a published protocol (Polyak et al., 2012).
For each replicate, 10 L4 worms were collected in 10 mL of a buffer contain-
ing 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 0.001% gelatin, and
5 mg/mL Proteinase K. The worms were then incubated at 65C for
75 min, followed by a 20-min incubation at 95C, and diluted with 10 mL
of H2O. Subsequently, 5.5 mL of each sample was used to run a TaqMan
assay with a Universal Master Mix (cat. no. 444040, Thermo Fisher
Scientific), where ND4 (cat. no. 4440043, assay ID: AIFAT8G) and ACT-4
(assay ID: Ce02508047_s1, Thermo Fisher Scientific) assays quantified
mtDNA and nDNA content, respectively. mtDNA copy numbers were then
normalized to nDNA content.
Oxygen Consumption
To measure oxygen consumption, we adapted a published protocol (Dancy
et al., 2016) and used approximately 300 L4 worms grown on plates to
the appropriate age and collected them in M9 media (22 mM KH2PO4,
42 mM Na2HPO4, 86 mM NaCl, and 1 mM MgSO4). The worms were
washed 3 times and aliquoted over 3–5 wells of a 24-well plate from Sea-
horse Biosciences containing 500 mL of M9 media. Images were made of
the wells to account for the exact number of worms deposited in each
well, and the plates were analyzed with a Seahorse Biosciences XF24
Extracellular Flux Analyzer in accordance with the following program: 10 cy-
cles of 2 min mixing, 2 min resting, and 2 min reading. This method demon-
strates a linear increase in oxygen consumption rate (OCR) reading with
increasing number of N2 and polg-1(srh1) worms (Figures S1A and S1B).
To assess maximal respiration, we injected carbonyl cyanide-4-(trifluoro-
methoxy)phenylhydrazone (FCCP) to a final concentration 25 mM, and ten
additional readings were made.
Oxidative State
For each data point, five age-matched worms with the roGFP::orp1 construct
were anesthetized on a 3% agarose pad with 10mM levamisole-HCl, and their
heads were imaged by excitation at 488 and 405 nm and emission at 500–
600 nm. Confocal images were analyzed using ZEN Black software where
the total fluorescence emitted by the excitation of each wavelength was calcu-
lated in arbitrary units (Figure S2C). Heads of WT and generation-matched
polg-1(srh1) worms without the roGFP::orp1 construct were imaged using
the same experimental parameters to ascertain autofluorescence and correct
the data (Figure S2D). The 405-nm fluorescence was divided by the fluores-
cence produced by 488 nm to ascertain the oxidative state of the animal.
The average of the oxidative state of all animals in a group is reported. This
method was adapted from a published protocol (De Henau et al., 2015).
WT animals with the construct were treated with paraquat to ascertain the
sensitivity of the construct (Figures S2E and S2F).
Chemotaxis
This protocol has been previously published (Kashyap et al., 2012; Wes and
Bargmann, 2001). Briefly, 30 to 50 age-matched worms were collected and
washed in M9 buffer. These worms were placed 5 cm away from a spot with
2 mL of 10% isoamyl alcohol in 100% ethanol and 1 mL 10% sodium azide.
The worms were then allowed to crawl toward the chemo-attractant for 1 hr,
after which the distance between the chemo-attractant and individual worms
was noted and measured using ImageJ software. Studies involving urolithin A
were performed by placing parents on plates containing 50 mM urolithin A. L4
progeny were collected on the third day and placed onto fresh plates with
urolithin A every 2 days prior to chemotaxis on day 7.
Gentle Touch
Appropriately aged worms were gently touched with an eyelash attached to
the end of a pick on their head and their tail. These touches were repeated
5 times for a total of ten touches, and any movement in the opposite direction
was counted as a response. At least 20wormswere tracked longitudinally over
a time span of 10 days, with measurements taken every 2 days (adapted from
Hobert et al., 1999).Thrashing
Thrashing assays were performed by placing 5–6 appropriately aged worms in
a 25-mL drop of M9 buffer on a glass slide per movie. They were allowed to
acclimate for 1 min, and then a 1 min long time-lapse movie was obtained at
16.7 frames per second. At least five movies using different sets of five individ-
uals were made for each data point. Each movie was processed using the
ImageJ plugin ‘‘wrmtrck’’ (Nussbaum-Krammer et al., 2015). The average
body bends per second for each movie pertaining to a single genotype and
age were averaged. Six to ten replicate movies were assayed per genotype
and age.
Lifespan
For each strain, three replicates of at least 30 L4 worms were grown at 20C
and transferred onto fresh a plate every other day. Each day, the worms
were observed to identify live and dead animals. Worms that were not visibly
moving were gently prodded, observed for a response, and counted as dead if
there was no response, after which they were removed from the plate. Worms
that escaped or died due to bagging or bursting were omitted from the final
analysis.
Mitochondrial Genome Sequencing
Single worms were boiled at 65C for 75 min and 20 min at 95C in 10 mL of
buffer containing 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 0.001%
gelatin, and 5 mg/mL Proteinase K. They were diluted with 10 mL of water,
and four 100 mL PCR reactions were carried out per worms using Kapa
HiFi polymerase (cat. no. KK2102, Kapa Biosystems) to amplify 11 kb of
mitochondrial DNA (Figure S4A). Primer sequences and details for amplifica-
tion cycling are denoted in Figure S4. The resultant electrophoretograms
were scanned for double peaks to indicate heteroplasmic mutations arising
in the mtDNA and aligned against WT mtDNA to identify homoplasmic
mtDNA mutations.
Random Mutation Capture and Mutation Spectrum
The original protocol (Vermulst et al., 2007) was modified from using DNA
isolated from mitochondrial preps to using whole-genome preps. Briefly,
we sorted 2,000 homozygous polg-1(srh1) worms and performed whole-
genome preps. 10–20 mg of total DNA was digested with TaqaI restriction
enzyme (cat. no. R0149T, New England Biolabs) for 10 hr, with 1 mL of fresh
enzyme added every hour. Digested DNA was amplified by qPCR or digital
droplet PCR using two primer sets to measure total mtDNA copy
number and mutant mtDNA copy number. PCR reactions across TaqaI sites
that record mutant mtDNA molecules were digested with TaqaI post-PCR
to determine that digestion was complete, and mtDNA mutation rates








To separate the individual mutations, amplicons were diluted to a single-
molecule level and PCR amplified separately and then sequenced.
RNAi
We used RNAi constructs from the Arhinger library and adapted the protocol
from the Ahringer laboratory (Kamath and Ahringer, 2003). For RNAi treat-
ments, WT or polg-1(srh1) heterozygote parents were placed on plates
spotted with bacteria that had the L4440 (no RNAi) or RNAi construct of inter-
est. On the third day, L4 progeny were placed on fresh L4440 or RNAi plates
and transferred to fresh plates on days 2 and 4. If the RNAi caused any devel-
opmental defects, then L4 progeny from the L4440 plates were placed on the
RNAi plates. On the fifth day of the adulthood, the chemotaxis assay was per-
formed as described above.Cell Reports 22, 3115–3125, March 20, 2018 3123
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Figure S1A, Related to Figure 1. Expression of the V5-tagged IDH1 WT and R132H constructs is similar between the 
paired lines, and remains constant with continuous culture. B:  Incorporation of 13C from 13C6-glucose into aspartate 
through oxidative pathways  (red) is unchanged between IDH1 WT and IDH1 R132H-expressing cells. C: 13C incorpo-
ration from 13C5-glutamine into aspartate is unchanged between IDH1 WT and R132H-expressing cells. D: Sequencing 
results confirming successful transduction of R132H-mutated IDH1 (right) into LN18 parental cell lines (left). E: As for 
(D), but IDH2 R172K. Synthesis of proline from glutamate is increased in an IDH1 R132H-expressing (F), but not 
IDH2 R172K-expressing (G) LN18 cell line. Expression of IDH1 R132H (H) or R172K (I) in the LN18 parental cell 
line results in increased extracellular 2HG levels. J: IDH1 R132H-expressing HOG cells demonstrate increased 
PYCR1-mediated proline synthesis and excretion in the presence of exogenous 200 µM proline. Data presented show 
extracellular 13C5-proline as a proportion of total extracellular proline. K: 2HG excreted into the medium in early 
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Figure S2A, Related to Figure 2: LN18 IDH1 R132H-expressing cells do not demonstrate increased expression in proline biosynthetic 
enzymes. B: Relative mRNA expression of the three mitochondrial proline biosynthetic enzymes, ALDH18A1 (pyrroline 5-carboxylate 
synthetase), PYCR1 and PYCR2 shows that there is no difference between the IDH1 WT and IDH1 R132H-expressing HOG cells. C: 
Immunoblot showing successful knockdown of PYCR1 in LN18 cells. D: LN18 cells expressing IDH1 R132H synthesize increased 
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Figure S3A and B, Related to Figure 3: Representative spectra from GC-MS analysis of gliomas showing a ‘no 2HG’ (A) and high 
2HG (B) sample. The ion at m/z 433 was used, with glutamate retention used as a control. C: PYCR1 densitometry normalised to 
protein loaded. D: Additional glioma samples blotted for PYCR1 (Figure 3C), separated by their tumoral 2HG levels, showing 












Figure S4A and B, Related to Figure 4: Knockdown of PYCR1 alters the NAD+:NADH ratio in IDH1 R132H-expressing 
HOG (A) and LN18 (B) cells. No change is observed in IDH1 WT cells. ‘*’ p<0.05, 2-way ANOVA with post-test. C: In 
common with the R132H-expressing HOG cells, cytosolic pyruvate:lactate ratio is unchanged after siPYCR1 in LN18 cell line. 
D: PYCR1 knockdown does not significantly alter the GSH:GSSG ratio in either wild-type or IDH1 R132H-expressing HOG 
(left) or LN18 (right) cells. E: siPYCR1 does not alter mitochondrial ROS production as measured using mitoSOX. AntiA, 
antimycin A positive control treatment of IDH1 WT cells. F: Knockdown of PYCR1 in R132H-expressing LN18 cells results 
in increased respiration. G: Oxidative aspartate synthesis is maintained in IDH1 R132H-expressing cells in limiting oxygen 




Table S1, Related to Figure 3C: Patient characteristics for samples used in Figure 3C. Abbreviations: 
AA; Anaplastic astrocytoma, AO; Anaplastic oligodendroglioma, AOA; Anaplastic oligoastrocytoma, 
GBM; Glioblastoma. 
 
Lane # on 
Figure 3C 
Age Gender Diagnosis Sequencing IHC for IDH1(H09) 
1 62 M GBM Wild Type (－) 
2 64 M GBM Wild Type (－) 
3 46 M AA Wild Type (－) 
4 44 M GBM Wild Type (－) 
5 39 F Oligodendroglioma Wild Type (－) 
6 41 F GBM Wild Type (－) 
7 52 M GBM Wild Type (－) 
8 27 M Astrocytoma IDH1 R132H (＋) 
9 50 M Oligoastrocytoma IDH1 R132H (＋) 
10 32 F Astrocytoma IDH1 R132H (＋/－) 
11 27 F Astrocytoma IDH1 R132H (－) 
12 39 F Astrocytoma IDH1 R132H (＋) 
13 50 M AA IDH1 R132H (＋/－) 
14 31 F GBM IDH1 R132H (＋) 
Table S2 
 
Table S2, Related to Figure 3E: Patient characteristics for samples used in GC-MS analysis of metabolites 
shown in Figure 3E. Abbreviations: AA; Anaplastic astrocytoma, AO; Anaplastic oligodendroglioma, AOA; 
Anaplastic oligoastrocytoma, AUC; area under the curve, GBM; Glioblastoma. 
 
Diagnosis Age Gender 2-HG AUC Proline AUC 
AA 50 M 1220042 1337921 
AO 50 M 1261259 378305 
GBM 56 F 47727954 20927301 
Astrocytoma 27 F 1721976 3137530 
Astrocytoma 32 F 31887460 45294696 
GBM 61 M 20320432 25663090 
Astrocytoma 27 M 28661710 45244078 
Astrocytoma 39 F 4356405 1093566 
AA 30 M 39642469 29777748 
AO 53 F 72633527 84155405 
Oligodendroglioma 43 M 22556824 58044269 
GBM 31 F 137027818 86226588 
GBM 31 F 33629589 4564017 
Astrocytoma 29 M 125998378 34281034 
OA 50 M 97829567 61572655 
OA 34 M 14875269 47941656 
Supplemental Experimental Procedures  
All chemicals were from Sigma (UK) unless otherwise specified. 
Molecular cloning and cell transduction with lentiviral vectors 
Human IDH2 cDNA was amplified by PCR using primers, which added 1X-FLAG tag to the 
3’ end of the sequence. This was cloned as ClaI-NheI fragment into the 
pCC.sin.36.MCS.PPTWpre.CMV.tTA-S2tet lentiviral transfer vector. Subsequently a 
recombinant PCR-based approach, using IDH2 cDNA as a template was applied to 
construct the IDH2 R172K mutant, which was cloned into the same lentiviral transfer vector 
as a ClaI-Nhe fragment, by substituting the IDH2 cassette with the IDH2-R172K mutant 
cassette. As a control, cells were transduced with a pCC.sin.36.eGFP.PPT.Wpre.CMV.tTA-
s2tet, encoding eGFP and pCC.sin.36.IDH2WT.PPTWpre.CMV.tTA-S2tet, encoding the wild 
type sequence of human IDH2. PCR primers for the above are available upon request. 
Human IDH1 wild type and R132H mutant vectors, vector stocks and titration were prepared 
as described in (Bardella et al., 2016). 
Cell culture 
ON_TARGETplus pools used were: (L-012349-00 [PYCR1], L-016646-00 [PYCR2] or D-
001810-10 [non-targeting]; Thermo Fisher, UK) at 25 nM using DharmaFECT 1 transfection 
reagent (Thermo Fisher, UK) 24 h post seeding. Cells were lysed at various time points 
post-transfection (see Figures for details) to evaluate knockdown. 
Quantitative real-time PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 74104) according to the 
manufacture’s protocol. 1 µg RNA per sample was subjected to reverse transcription using 
Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) kit (Promega, M1701). 
10 µL of the resulting cDNA was used with TaqMan® gene expression master mix (AB, 
4369016) for quantitative real-time PCR using AB 7500 Real Time PCR System. The 
following primers and probes were used: PYCR1 (Hs01048016_m1), PYCR2 
(Hs01016460_gH), ALDH18A1 (Hs00913261_m1), ACTIN (Hs01060665_g1) (ThermoFisher 
Scientific). The expression of ALDH18A1, PYCR1 and PYCR2 were normalised to actin as 
housekeeping gene. Comparative analysis across samples was calculated using the 2-ΔΔCT 
method. 
O2 Consumption Measurements 
Cells were seeded at 2 x 105 onto 6-well plates in standard culture conditions and were 
transfected 24 h later with targeting siRNA against PYCR1 and PYCR2. The cells were 
harvested and re-suspended in complete media. 4 x 105 cells in 300 µl were added to the 
electrode chamber and the oxygen consumption rate was measured over a 5 min period 
using Oxygraph software (http://www.hansatech-instruments.com/). Cells were kept in 
suspension using a stirring bar and the chamber temperature was maintained at 37°C 
through the use of a heating block. After recording for 5 min, KCN 700 µM (Sigma-Aldrich, 
60178) was added to the electrode chamber to inhibit cellular respiration and the oxygen 
consumption was measured for a further 3 min. The final respiration rate was obtained by 
subtracting the oxygen consumption rate in presence of KCN to the oxygen consumption 
rate in the absence of KCN. 
 
NMR Spectroscopy 
4 x 106 cells were plated onto 15 cm dishes and cultured in standard medium overnight. 
Media was replaced with basic formulation DMEM supplemented with 13C6 glucose or 13C5 
glutamine at 10 mM and 2 mM respectively for 24 h prior to extraction. At the conclusion of 
tracer experiments, cells were washed with ice-cold 0.9% saline solution and extracted in 
1.2 mL pre-chilled methanol (-20oC), water (4oC) and chloroform (-20oC) in a 1:1:1 ratio. Cell 
lysates were vortexed for 15 min at 4oC and immediately centrifuged at 15,000 g for 15 min 
at 4oC. Extraction was performed on three different cultures for each labelling experiment.  
Dried samples were re-suspended in 60 µL of 100 mM sodium phosphate buffer (pH7.0) 
containing 500 µM DSS and 2 mM Imidazole, 10% D20, pH 7.0. Samples were vortexed, 
sonicated (5-15 min) and centrifuged briefly, before transferred to 1.7 mm NMR tubes using 
an automated Gilson.One-dimensional (1D)-1H-NMR spectra and two-dimensional (2D)-
1H,13C-Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) NMR spectra were 
acquired using a 600-MHz Bruker Avance III spectrometer (Bruker Biospin) with a TCI 
1.7 mm z-PFG cryogenic probe at 300 K. Spectral widths were set to 7,812.5 and 24,155 Hz 
for the 1H and 13C dimensions, respectively. 16,384 complex data points were acquired for 
the 1D-spectra and 512 complex data points were acquired for the 1H dimension of 2D-
1H,13C-HSQC NMR spectra. An exponentially weighted non-uniform sampling scheme was 
used for the indirect dimension. Here, 30% of 8,192 complex data points (2,458) were 
acquired. 128 transients were recorded for the 1D-NMR spectra with a relaxation delay of 
4 s, and two transients were recorded for the 2D-1H,13C-HSQC NMR spectra with a 
relaxation delay of 1.5 s. Each sample was automatically tuned, matched and then shimmed 
(1D-TopShim) to a DSS line width of <2 Hz before acquisition of the first spectrum. Total 
experiment time was ~15 min per sample for 1D-1H-NMR spectra and 4.5 h per sample for 
2D-1H,13C-HSQC NMR spectra. 1D-1H-NMR spectra were processed using the MATLAB-
based MetaboLab software (Ludwig and Gunther, 2011). All 1D data sets were zero-filled to 
131,072 data points before Fourier Transformation. The chemical shift was calibrated by 
referencing the DSS signal to 0 p.p.m. 1D-spectra were manually phase corrected. Baseline 
correction was achieved using a spline function (Ludwig and Gunther, 2011). 1D-1H-NMR 
spectra were exported into Bruker format for metabolite identification and concentration 
determination using Chenomx 7.0 (ChenomxINC). 2D-1H,13C-HSQC NMR spectra were 
reconstructed using compressed sensing in the MDDNMR and NMRpipe software (Delaglio 
et al., 1995; Kazimierczuk and Orekhov, 2011; Orekhov and Jaravine, 2011). The final 
spectrum size was 1,024 real data points for the 1H dimension and 16,384 real data points 
for the 13C dimension. Analysis was performed using MetaboLab and pyGamma software 
was used in multiplet simulations (Smith et al., 1994). The methyl group of lactate was used 
to calibrate the chemical shift based on its assignment in the human metabolome database 
(Wishart et al., 2013). 
 
GC-MS 
Cell analysis - cells were seeded at 2 x 105 onto 6-well plates in standard culture conditions 
and transfected with non-targeting RNA (siNT) and siRNA targeting PYCR1 (siPYCR1) and 
PYCR2 (siPYCR2) at 25 nM. Media was changed to basic formulation DMEM containing 
either 10 mM 13C6 glucose or 2 mM 13C5 glutamine with the other carbon source unlabelled, 
for 24 h prior to extraction. At the conclusion of tracer experiments, cells were washed with 2 
mL ice-cold 0.9% saline solution and quenched with 0.3 mL pre-chilled methanol (-20oC). 
After adding an equal volume of ice-cold HPLC-grade water containing 1 µg/mL D6-glutaric 
acid (C/D/N Isotopes Inc), cells were collected with a cell scraper and transferred to tubes 
containing 0.3 mL of chloroform (-20oC). The extracts were shaken at 1400 rpm for 20 min at 
4oC and centrifuged at 16,000 g for 5 min at 4oC. 0.3 mL of the upper aqueous phase was 
collected and evaporated in GC glass vials under vacuum at -4oC using a refrigerated 
CentriVap Concentrator (Labconco). Metabolite derivatization was performed using an 
Agilent autosampler. Dried polar metabolites were dissolved in 15 µl of 2% methoxyamine 
hydrochloride in pyridine (Thermo Fisher Scientific, 25104) at 55oC, followed by an equal 
volume of N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-
butyldimethylchlorosilane after 60 minutes, and incubation for a further 90 min at 55oC. 
GC-MS analysis was performed using an Agilent 6890GC equipped with a 30 m DB-35MS 
capillary column. The GC was connected to an Agilent 5975C MS operating under electron 
impact ionization at 70 eV. The MS source was held at 230oC and the quadrupole at 150oC. 
The detector was operated in scan mode and 1 µL of derivatised sample was injected in 
splitless mode. Helium was used as a carrier gas at a flow rate of 1 mL/min. The GC oven 
temperature was held at 80oC for 6 min and increased to 325oC at a rate of 10oC/min for 4 
min. The run time for each sample was 59 min. Measurements in selcted ion monitoring 
(SIM) mode were performed as described previously (Battello et al., 2016). For 
determination of the mass isotopomer distributions (MIDs), spectra were corrected for 
natural isotope abundance. Data processing from raw spectra to MID correction and 
determination was performed using MetaboliteDetector software (Hiller et al., 2009). 
 
Tumor metabolite analysis 
20 mg of tumor was mixed with 400 μL of 80% methanol, homogenized in a Tissuelyser-48 
(Shanghai Jingxin), and then centrifuged at 14,000 rpm for 10 min at 4°C. A 200 μL aliquot 
of supernatant was transferred to a screw-cap V-type glass-bottom vial and dried in a 
vacuum-drying apparatus at 30°C for 1 h. Methoxyamine hydrochloride was dissolved in 
pyridine at a concentration of 20 mg/mL; 35 µL of this solution was added to the sample, and 
then incubated at 70°C for 0.5 h. Derivatization was performed at 70°C for 40 min following 
addition of 20 µL of MTBSTFA. The sample (1 µL) was subjected to GC-MS, with a total run 
time of 32 min. A capillary column (HP-5ms Intuvo, 30 m × 0.25 mm × 0.25 μm; Agilent 
Technologies) using helium as a carrier gas was utilized for GC separation. The inlet model 
was splitless, and its temperature was 250°C. Parameters for GC-MS were as follows: 
100°C for 3 min; ramp 10°C/min to 140°C, 8°C/min to 260°C, and 10°C/min to 310 °C; and 
then hold for 5 min at 310°C. The total run time was 32 min. The temperature of the injector 
was set at 280°C, and that of the MSD Transfer Line was 290°C. Ion source was EI (70 eV) 
at a temperature of 230°C. Mass scan range was from 50 to 600 m/z. 
 
Redox measurements 
Cells were seeded at 2 x 104 onto 8-well chamber slides (Thistle Scientific, IB-80826) for 
NAD(P)H autofluorescence measurements, or 6 x 103 in 96-well plates for NAD:NADH 
assay. Both were transfected 24 h later with targeting and non-targeting siRNA against 
PYCR1 or PYCR2 where shown before NAD(P)H imaging or biochemical analysis 48 h later. 
NAD(P)H was excited at λ = 351/364 nm using the argon UV laser module on a Zeiss UV 
Axiovert confocal autofluorescence, and autofluorescence captured at λ = 385-470 nm using 
a photomultiplier tube (PMT) (1024 x 1024 pixels; 12-bit). Carbonyl cyanine m-chlorophenyl 
hydrazine (CCCP) 20 µM (Sigma-Aldrich, C2759) and Rotenone 60 µM (Sigma-Aldrich, 
R8875) were added to each well to achieve basal and maximal NAD(P)H autofluorescence, 
respectively. User-blinded offline analysis was performed using Fiji software (http://fiji.sc/) 
and 48-126 random visual fields were analyzed per experimental condition. Images 
presented were exported into ImageJ, and noise reduction performed using the ‘remove 
outliers’ function with standard settings. NAD:NADH assay (NAD/NADH GloTM Assay 
(Promega, G9071) was performed as per manufacturer’s protocol. 
 
ROS measurements 
Cells were seeded at 2 x 105 onto 6-well plates in standard culture conditions and as 
described above. To assay for ROS, media was replaced with HBSS before incubation with 
5 μM of MitoSOX Red (Thermofisher, M36008) at 37°C for 10 minutes. The cells were 
trypsinized and subsequently collected in HBSS with 1% FBS. Using an LSRFortessa X-20 
flow cytometer, fluorescence at 575nm was measured and mean fluorescence intensity of 
10,000 events in triplicate assessed using FloJo software.  
 
SRB assay 
Cells were treated with 50 nM rotenone for 72 h prior to being fixed in 20% (v/v) ice-cold 
trichloroacetic acid solution (TCA) (Sigma-Aldrich, T0699) for 30 min at 4oC. Plate wells 
were washed with water and once dry, intracellular protein was stained using 0.4% (w/v) 
sulfohodamine B (SRB) (Sigma-Aldrich, 230162) in 1% acetic acid for 10 min at room 
temperature. After washing with 1% acetic acid to reduce non-specific staining, SRB was 
dissolved in 50 mM Tris/HCl pH 8.8 once dry. 100 µL/well was aliquoted for quantification by 
absorbance at 495 nm on FLUOstar Omega (BMG LabTech). Final sample absorbance 
values were determined by calculating the mean blank-corrected absorbance for each 
replicate, where 50 mM Tris/HCl pH 8.8 alone was used as the blank. 
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